Tolfenamic acid in the treatment of rheumatoid arthritis

In an open trial of three months' duration the clinical effect of tolfenamic acid, a new nonsteroid anti-inflammatory analgesic, was found to be good in 85 patients suffering from rheumatoid arthritis. Both subjective and objective parameters clearly improved, and corticoid therapy could be abandoned by 21% of the patients. Tolfenamic acid was for the most part better than or as good as, the previous medication by which the disease had been brought to a stabile state. Side-effects were mild, no severe adverse reactions were observed which could be definitely attributed to tolfenamic acid.